

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

CHANGE OF DIRECTORS

The Board announces that each of Mr. WANG Qiang and Mr. WANG Lei has tendered his resignation as an executive Director and a non-executive Director, respectively, with effect from October 23, 2020.

The Board also announces that Mr. TU Yanwu has been appointed as an executive Director, with effect from October 23, 2020.

RESIGNATION OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Alibaba Health Information Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that each of Mr. WANG Qiang and Mr. WANG Lei has tendered his resignation as an executive Director and a non-executive Director, respectively, with effect from October 23, 2020.

Mr. WANG Qiang confirms that he has resigned to devote more time to personal commitment and development. Mr. WANG Lei confirms that he has resigned to concentrate on the other businesses of Alibaba Group Holding Limited. Each of Mr. WANG Qiang and Mr. WANG Lei confirms that he has no disagreement with the Board and there are no circumstances related to his resignation which need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company (the “**Shareholders**”).

The Company would like to thank Mr. WANG Qiang and Mr. WANG Lei for all of their past contributions to the Group.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. TU Yanwu (“**Mr. Tu**”) has been appointed as an executive Director, with effect from October 23, 2020.

Mr. Tu, aged 42, has been the chief financial officer of the Company since April 2020, who is responsible for the overall financial management and the formulation and implementation of the Group’s strategies. Prior to that, Mr. Tu was a senior finance director of the Group from September 2019 to March 2020, and was seconded to Guizhou Ensure Chain Pharmacy Company Limited* (貴州一樹連鎖藥業有限公司) to act as its chief financial officer and senior vice president from October 2018 to August 2019. Before joining the Group, Mr. Tu was the finance director of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (“**WuXi AppTec**”) from December 2015 to September 2018, where he led the accounting and reporting team since the delisting of WuXi PharmaTech (Cayman) Inc. from the New York Stock Exchange through the initial public offering and listing of WuXi AppTec on the Shanghai Stock Exchange. From April 2008 to April 2015, Mr. Tu held various finance positions at different departments of General Motors, including being in charge of special projects in the Asia-Pacific region and holding financial reporting and management positions in the North American region. Mr. Tu also had over five years of experience in auditing at Arthur Anderson and PricewaterhouseCoopers in Shanghai where he led the audit team to work on initial public offering and listing projects across different industries. Mr. Tu obtained a Bachelor of Arts Degree in Economics and Business Administration in June 2001 from Fudan University in the People’s Republic of China and he is also a member of the Chinese Institute of Certified Public Accountants.

As at the date of this announcement, Mr. Tu beneficially holds 38,500 ordinary shares of the Company and, subject to vesting, he is interested in 1,088,500 ordinary shares of the Company underlying 145,000 share options and 943,500 restricted share units granted to him in accordance with the share award scheme of the Company, pursuant to Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “**SFO**”). Save as disclosed above, Mr. Tu is not interested or deemed to be interested in any shares or underlying shares of the Company pursuant to Part XV of the SFO.

Save as disclosed in this announcement, Mr. Tu does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company.

Save as disclosed in this announcement, Mr. Tu did not hold any directorship in any other Hong Kong or overseas listed public companies in the last three years and does not hold any other position with the Company or other members of the Group.

* *For identification purpose only*

Mr. Tu has entered into an appointment letter with the Company for a term of one year, which is renewable for a one-year period upon expiry of each term. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the bye-laws of the Company and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The appointment letter does not specify Mr. Tu’s remuneration as an executive Director. Mr Tu’s remuneration as an executive Director is expected to be determined by the Board with reference to his experience and prevailing market levels, and the Company will disclose such details as soon as practicable. Save as disclosed herein, Mr. Tu has confirmed that there is no other information that is required to be disclosed in accordance with Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter relating to his appointment that needs to be brought to the attention of the Shareholders.

The Board would like to congratulate Mr. Tu on his new appointment.

By Order of the Board
Alibaba Health Information Technology Limited
Zhu Shunyan
Chairman and Chief Executive Officer

Hong Kong, October 23, 2020

As at the date of this announcement, the Board comprises seven Directors, of which (i) two are executive Directors, namely Mr. ZHU Shunyan and Mr. TU Yanwu; (ii) two are non-executive Directors, namely Mr. WU Yongming and Mr. XU Hong; and (iii) three are independent non-executive Directors, namely Mr. LUO Tong, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei (Vanessa).